Literature DB >> 25023513

Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies.

Anna Borisovskaya1, Marcella Pascualy, Soo Borson.   

Abstract

This update on Alzheimer's disease (AD) discusses treatment strategies for cognitive and neuropsychiatric symptoms (such as agitation, psychosis, anxiety, and depression) common in this illness, emphasizing in particular nonpharmacologic strategies such as cognitive interventions, physical exercise, and psychotherapy. We provide an overview of cognitive enhancers and their combination strategies and medications commonly used for treatment of neuropsychiatric symptoms in AD. Finally, we give recommendations for providing support to caregivers and suggest how to identify caregiver/patient pairs most in need of intensive dementia care services.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25023513     DOI： 10.1007/s11920-014-0470-z

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  87 in total

1.  Depressive symptoms and level of physical activity in patients with Alzheimer's disease.

Authors:  Thays Martins Vital; Salma S Soleman Hernandez; Angelica Miki Stein; Marcelo Garuffi; Danilla Icassatti Corazza; Larissa Pires de Andrade; José Luiz Riani Costa; Florindo Stella
Journal:  Geriatr Gerontol Int       Date:  2012-02-02       Impact factor: 2.730

2.  Sertraline for the treatment of depression in Alzheimer disease.

Authors:  Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-02       Impact factor: 4.105

3.  Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Authors:  J S Street; W S Clark; K S Gannon; J L Cummings; F P Bymaster; R N Tamura; S J Mitan; D L Kadam; T M Sanger; P D Feldman; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-10

Review 4.  Best practices interventions to improve quality of care of people with dementia living at home.

Authors:  Adelaida Zabalegui; Jan P H Hamers; Staffan Karlsson; Helena Leino-Kilpi; Anna Renom-Guiteras; Kai Saks; Maria Soto; Caroline Sutcliffe; Esther Cabrera
Journal:  Patient Educ Couns       Date:  2014-01-30

Review 5.  Progress in Alzheimer's disease research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2013-04-18       Impact factor: 4.849

Review 6.  Management of behavioral problems in Alzheimer's disease.

Authors:  Serge Gauthier; Jeffrey Cummings; Clive Ballard; Henry Brodaty; George Grossberg; Philippe Robert; Constantine Lyketsos
Journal:  Int Psychogeriatr       Date:  2010-01-25       Impact factor: 3.878

7.  Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria.

Authors:  Edmond Teng; John M Ringman; Leslie K Ross; Ruth A Mulnard; Malcolm B Dick; George Bartzokis; Helen D Davies; Douglas Galasko; Linda Hewett; Dan Mungas; Bruce R Reed; Lon S Schneider; Freddi Segal-Gidan; Kristine Yaffe; Jeffrey L Cummings
Journal:  Am J Geriatr Psychiatry       Date:  2008-06       Impact factor: 4.105

Review 8.  Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.

Authors:  George T Grossberg; Vojislav Pejović; Michael L Miller; Stephen M Graham
Journal:  Dement Geriatr Cogn Disord       Date:  2009-02-05       Impact factor: 2.959

9.  Mirtazapine is associated with less anxiolytic use among elderly depressed patients in long-term care facilities.

Authors:  Marie E Gardner; Daniel C Malone; Mark Sey; Maude A Babington
Journal:  J Am Med Dir Assoc       Date:  2004 Mar-Apr       Impact factor: 4.669

Review 10.  Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Authors:  Chris G Parsons; Wojciech Danysz; Andrzej Dekundy; Irena Pulte
Journal:  Neurotox Res       Date:  2013-05-09       Impact factor: 3.911
View more
  5 in total

Review 1.  Agitation and Irritability in Alzheimer's Disease: Evidenced-Based Treatments and the Black-Box Warning.

Authors:  Aaron M Koenig; Steven E Arnold; Joel E Streim
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

2.  Effect of a high-intensity exercise program on physical function and mental health in nursing home residents with dementia: an assessor blinded randomized controlled trial.

Authors:  Elisabeth Wiken Telenius; Knut Engedal; Astrid Bergland
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 3.  Alzheimer's disease treatment: The share of herbal medicines.

Authors:  Masoud Soheili; Mohammad Karimian; Gholamali Hamidi; Mahmoud Salami
Journal:  Iran J Basic Med Sci       Date:  2021-02       Impact factor: 2.699

Review 4.  A Review on Potential Mechanisms of Terminalia chebula in Alzheimer's Disease.

Authors:  Amir R Afshari; Hamid R Sadeghnia; Hamid Mollazadeh
Journal:  Adv Pharmacol Sci       Date:  2016-01-28

5.  Multi-Target Screening and Experimental Validation of Natural Products from Selaginella Plants against Alzheimer's Disease.

Authors:  Yin-Hua Deng; Ning-Ning Wang; Zhen-Xing Zou; Lin Zhang; Kang-Ping Xu; Alex F Chen; Dong-Sheng Cao; Gui-Shan Tan
Journal:  Front Pharmacol       Date:  2017-08-25       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.